Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer
- PMID: 31646745
- DOI: 10.1111/coa.13466
Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer
Abstract
Objective: To investigate the role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of cervical metastases in papillary thyroid cancer. Our hypothesis is that level of expression of MMPs and TIMPs is associated with the development of cervical metastases and the pattern of metastatic process in papillary thyroid cancer.
Design: This research retrospectively investigates the expression of MMP-1, -2 and -9 as well as TIMP-1 and -2 in papillary thyroid carcinoma tissue. Tissue specimens were immunohistochemically treated with primary monoclonal antibodies against MMP-1, MMP-2, MMP-9, TIMP-1 and TIMP-2.
Setting: Single-centre study.
Participants: In total, samples of 159 patients were analysed. In all patients, total thyroidectomy was performed, whereas 102 patients underwent selective neck dissection of either central (level VI) or lateral neck (level II-V). Subjects were divided into four groups.
Main outcome measures: Matrix metalloproteinases and TIMPs expression values were analysed in each group, and groups were compared to each other.
Results: Total number of patients was 159, of which 125 were women and 34 men. Comparing expression levels of MMPs and TIMPs in metastatic (study groups) and non-metastatic (control group), papillary thyroid carcinomas yielded significant differences in MMP-1 and TIMP-1 expression levels, where the highest expression values were found in the group with metastasis in lateral neck. Expression levels of MMP-2, MMP-9 and TIMP-2 did not differ statistically significant among the groups.
Conclusion: Elevated expression of MMP-1 and TIMP-1 in tumour tissue can be considered a predictive factor for the development of metastases.
Keywords: matrix metalloproteinases-1; matrix metalloproteinases-2; neck dissection; papillary thyroid cancer; thyroidectomy; tissue inhibitor of metalloproteinases-1; tissue inhibitor of metalloproteinases-2.
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.Virchows Arch. 2001 Feb;438(2):121-8. doi: 10.1007/s004280000286. Virchows Arch. 2001. PMID: 11253113
-
Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer.Biomedicines. 2022 Dec 8;10(12):3178. doi: 10.3390/biomedicines10123178. Biomedicines. 2022. PMID: 36551933 Free PMC article.
-
Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.Cancer Biomark. 2011-2012;11(1):49-58. doi: 10.3233/CBM-2012-0258. Cancer Biomark. 2011. PMID: 22820140
-
Matrix metalloproteinases and the thyroid.Thyroid. 2000 Dec;10(12):1061-9. doi: 10.1089/thy.2000.10.1061. Thyroid. 2000. PMID: 11201850 Review.
-
Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma.Surg Oncol. 2011 Mar;20(1):e18-22. doi: 10.1016/j.suronc.2010.08.004. Epub 2010 Sep 29. Surg Oncol. 2011. PMID: 20880700 Review.
Cited by
-
Matrix Metalloproteinase 9/microRNA-145 Ratio: Bridging Genomic and Immunological Variabilities in Thyroid Cancer.Biomedicines. 2023 Nov 1;11(11):2953. doi: 10.3390/biomedicines11112953. Biomedicines. 2023. PMID: 38001954 Free PMC article.
-
Role of prophylactic central neck lymph node dissection for papillary thyroid carcinoma in the era of de-escalation.World J Clin Oncol. 2023 Jul 24;14(7):247-258. doi: 10.5306/wjco.v14.i7.247. World J Clin Oncol. 2023. PMID: 37583949 Free PMC article. Review.
-
The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.Molecules. 2023 Apr 25;28(9):3705. doi: 10.3390/molecules28093705. Molecules. 2023. PMID: 37175113 Free PMC article. Review.
-
Proteomics profiling for the global and acetylated proteins of papillary thyroid cancers.Proteome Sci. 2023 Apr 26;21(1):6. doi: 10.1186/s12953-023-00207-8. Proteome Sci. 2023. PMID: 37101287 Free PMC article.
-
FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.BMC Pulm Med. 2023 Jan 23;23(1):32. doi: 10.1186/s12890-022-02303-5. BMC Pulm Med. 2023. PMID: 36690987 Free PMC article.
References
REFERENCES
-
- Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones (Athens). 2010;9:103-108.
-
- Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 2000;6:469-476.
-
- Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144-1152.
-
- Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221-233.
-
- Gillian M. Tissue inhibitors of metalloproteinases. Genome Biol. 2011;12:233.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
